Palantir Blasted to a New All-Time High Today. Is the Stock Still a Buy?

The Motley Fool
Updated
Mitrade
coverImg
Source: Shutterstock

After a week or so when investors were more focused on the stock's lofty valuation and concerns about the momentum of artificial intelligence (AI) adoption, Palantir Technologies (NYSE: PLTR) delivered a third-quarter report on Tuesday morning that helped the stock shake off its brief malaise and sent it sharply higher. In fact, it rose by as much as 24.1% and hit a new all-time high. As of 1:51 p.m. ET, the stock was still up by 22.2% for the day.

After a jump of that magnitude, some investors may wonder if it's simply too late to buy the stock.

Bullish signals abound

Palantir has been on a blistering rally since the advent of generative AI early last year, with the stock up by around 689% (as of this writing). The company's AI-powered data mining solutions were already used widely by agencies of the U.S. government and its allies, but the debut of Palantir's Artificial Intelligence Platform (AIP) has taken its U.S. commercial revenue to the next level.

Some analysts and industry watchers have expressed concerns as to whether the company's growth streak could continue, but the seemingly insatiable demand for AI solutions was evident in Palantir's latest results. In the third quarter, revenue grew 30% year over year to $726 million, far outpacing the high end of management's forecast and analysts' consensus estimates, which were both at roughly $701 million.

The results were fueled by U.S. commercial revenue, which soared by 54% and now accounts for 25% of total revenue. Furthermore, its U.S. commercial customer count climbed by 79%. The company's potential to expand its user base well beyond its defense and intelligence industry roots is seen as critical to Palantir's future success, and its progress in that regard has been undeniable. Additionally, the company's profits continued to expand as earnings per share (EPS) climbed 43%.

The quintessential question

The issue of Palantir's valuation remains. Wall Street is forecasting EPS of $0.43 next year, which means the stock is still selling for more than 100 times forward earnings -- so it won't be a fit for every investor.

However, Palantir maintains a unique position in the AI ecosystem, having perfected its craft over more than two decades. Its "boot camps" give potential customers a way to work side by side with Palantir engineers to see how they would develop AI solutions that are directly relevant to their business needs.

I am confident in Palantir's prospects, which is why I've been adding to my position. For those who are leery of its valuation, I would suggest using a dollar-cost averaging strategy or buying on any weakness.

* The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

goTop
quote
Do you find this article useful?
Related Articles
placeholder
India’s economy is tumbling, and it might take whole world down with itIndia’s economy is spiraling. The rupee is sinking like a stone, dragging with it a mix of trade deficits, shrinking capital inflows, and uncertainty. The country’s economy has quickly become so important that if it plummets, the global economy will be at stake.
Author  Cryptopolitan
7 hours ago
India’s economy is spiraling. The rupee is sinking like a stone, dragging with it a mix of trade deficits, shrinking capital inflows, and uncertainty. The country’s economy has quickly become so important that if it plummets, the global economy will be at stake.
placeholder
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.
Author  The Motley Fool
7 hours ago
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.
placeholder
Novo Nordisk Sees Retail Buying Despite Wall Street CutsShares of leading weight-loss drugmaker Novo Nordisk (NVO.US) plunged after disappointing results from its latest weight-loss drug trial. Despite analysts slashing their price targets, retail investors flooded into the stock with massive buy-the-dip activity.
Author  Mitrade
13 hours ago
Shares of leading weight-loss drugmaker Novo Nordisk (NVO.US) plunged after disappointing results from its latest weight-loss drug trial. Despite analysts slashing their price targets, retail investors flooded into the stock with massive buy-the-dip activity.
placeholder
The Year of Concentration, Crypto, ChinaWhy 2024 was such a good year for investors, and the concerns they have about valuations and market concentration as they look ahead to 2025.
Author  The Motley Fool
15 hours ago
Why 2024 was such a good year for investors, and the concerns they have about valuations and market concentration as they look ahead to 2025.
placeholder
Prediction: This Energy Stock Will Deliver Substantial Market-Beating ReturnsExplore the exciting world of Chart Industries (NYSE: GTLS) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Author  The Motley Fool
15 hours ago
Explore the exciting world of Chart Industries (NYSE: GTLS) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!